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rationale: Barriers to developing treatments for human status epilepticus include 
the inadequacy of experimental animal models. In contrast, naturally occurring canine 
epilepsy is similar to the human condition and can serve as a platform to translate 
research from rodents to humans. The objectives of this study were to characterize the 
pharmacokinetics of an intravenous (IV) dose of topiramate (TPM) in dogs with epilepsy 
and evaluate its effect on intracranial electroencephalographic (iEEG) features.
Methods: Five dogs with naturally occurring epilepsy were used for this study. Three 
were getting at least one antiseizure drug as maintenance therapy including phenobarbi-
tal (PB). Four (ID 1–4) were used for the 10 mg/kg IV TPM + PO TPM study, and three (ID 
3–5) were used for the 20 mg/kg IV TPM study. IV TPM was infused over 5 min at both 
doses. The animals were observed for vomiting, diarrhea, ataxia, and lethargy. Blood 
samples were collected at scheduled pre- and post-dose times. Plasma concentrations 
were measured using a validated high-performance liquid chromatography-mass spec-
trometry method. Non-compartmental and population compartmental modeling were 
performed (Phoenix WinNonLin and NLME) using plasma concentrations from all dogs in 
the study. iEEG was acquired in one dog. The difference between averaged iEEG energy 
levels at 15 min pre- and post-dose was assessed using a Kruskal–Wallis test.
results: No adverse events were noted. TPM concentration–time profiles were best 
fit by a two compartment model. PB co-administration was associated with a 5.6-fold 
greater clearance and a ~4-fold shorter elimination half-life. iEEG data showed that TPM 
produced a significant energy increase at frequencies >4 Hz across all 16 electrodes 
within 15 min of dosing. Simulations suggested that dogs on an enzyme inducer would 
require 25 mg/kg, while dogs on non-inducing drugs would need 20 mg/kg to attain the 
target concentration (20–30 μg/mL) at 30 min post-dose.
conclusion: This study shows that IV TPM has a relatively rapid onset of action, loading 
doses appear safe, and the presence of PB necessitates a higher dose to attain targeted 
concentrations. Consequently, it is a good candidate for further evaluation for treatment 
of seizure emergencies in dogs and people.
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inTrODUcTiOn
Status epilepticus (SE) is defined as a condition characterized 
by abnormally prolonged seizures that can lead to long-term 
consequences, including permanent neuronal injury (1). SE has 
been reported to have an incidence between 2.5 and 59% in dogs 
with idiopathic epilepsy (2–4), and 32% in dogs with secondary 
epilepsy (3). In dogs that have had at least one episode of SE, 
overall mortality rates (primarily from euthanasia) were 32–38% 
(2, 5). In humans, SE occurs with an incidence between 0.04 and 
0.06% in the United States, resulting in an overall mortality rate 
of 22% (6). While benzodiazepines are the standard first line of 
care for SE in both dogs and humans (7, 8), approximately one-
third of humans fail to respond to first-line therapy (9). There 
remains a need for safe alternatives for early and rapid first- and/
or second-line therapy of SE to reduce the probability of recurring 
seizures, minimize associated complications, and improve patient 
outcomes.
One of the barriers to developing new treatments for SE is 
the experimental model used to find and evaluate investigational 
therapies. Oftentimes in rodent models, epilepsy is induced by 
chemical or electrical insult and may not be truly representative 
of epilepsy pathophysiology (10). Dogs with naturally occurring 
epilepsy have been proposed as appropriate models to examine 
new antiepileptic therapies prior to human trials (11). Canine 
epilepsy is strikingly similar to the human condition in both 
disease presentation and response to treatment. Holliday et  al. 
demonstrated that intracranial electroencephalograms (EEGs) of 
dogs and humans during focal onset seizure are indistinguish-
able (12). Moreover, studies of antiseizure drugs (ASDs), such as 
fosphenytoin and levetiracetam, have shown comparable efficacy 
in both dogs and humans for SE (11, 13). Given these similarities, 
assessing new therapies for SE in dogs will facilitate drug develop-
ment and increase the chance of successful translation for both 
canine and human SE.
Among the newer ASDs with injectable formulations, 
topiramate (TPM) is an attractive candidate for evaluation in the 
treatment of SE. TPM is the second-generation, broad-spectrum 
ASD that inhibits of voltage-gated sodium channels and enhances 
gamma-aminobutyrate (GABA) activity at specific GABAA recep-
tor subtypes (14). TPM also has mechanisms of action that differ 
from those exhibited by current therapies, including antagoniz-
ing AMPA/kainate glutamate receptors, and inhibiting specific 
carbonic anhydrase isozymes. Specifically in rodent studies of 
SE and ischemia, TPM has exhibited neuroprotection (15, 16). 
There are also several clinical reports in which TPM suspensions 
administered in humans via nasogastric tube was associated with 
seizure cessation in refractory SE. In both adults and children as 
young as 4.5 months, plasma concentrations of 2–40 μg/mL were 
associated with resolution of refractory SE (17–23).
Our group has studied the pharmacokinetics (PK) of a novel 
intravenous (IV) TPM formulation in humans. However, the PK 
of IV TPM has not been characterized in dogs. Furthermore, 
while oral TPM might be useful in dogs, there is limited infor-
mation on oral PK and no information in dogs with naturally 
occurring epilepsy on antiseizure medications (24). The aims of 
this study were to (1) characterize TPM PK following an IV and 
oral dose and (2) simulate doses to attain target concentrations 
of 20–30 μg/mL, upper range of concentrations that have been 
associated with efficacy in humans. As an exploratory analysis, 
we also report the effect of IV TPM on intracranial electroen-
cephalographic (iEEG) features in one dog.
MaTerials anD MeThODs
study animals and safety Monitoring
Five dogs with naturally occurring epilepsy were used in this 
study. Three of the dogs have uncontrolled seizures despite being 
on antiseizure maintenance regimens. Approval was obtained 
through the Institutional Animal Care and Use Committee of the 
University of Minnesota prior to the initiation of the study. The 
dogs were housed at the University of Minnesota’s Veterinary 
College. Each dog was previously implanted with a device 
which wirelessly transmits iEEG recordings (25, 26). Dogs were 
monitored throughout the study for vomiting, diarrhea, and 
lethargy prior to and for 90 min after drug administration, and 
at each blood sampling time. In the event of a seizure emergency 
(seizure lasting >5  min) or repetitive seizures (2+ seizures 
within 1 h, or 3+ seizures within 4 h), the on call veterinarian 
received an automated text message and confirmed the seizure 
activity using remote video monitoring. The rescue therapy 
protocol consisted of midazolam 12 mg administered as a single 
intramuscular dose.
study Drug
For this study, a stable isotope-labeled TPM compound contain-
ing six 13C, resulting in a mass 6  U greater than the unlabeled 
molecule was used for the IV formulation (10  mg/mL in 10% 
Captisol®). This formulation was manufactured by the University 
of Iowa under Good Manufacturing Practices and has been 
licensed to Ligand/CuRx Pharmaceuticals. Unlabeled TPM tablets 
(25 mg) purchased from the University of Minnesota Veterinary 
Pharmacy (Cipla USA, Inc.) were used for the oral treatment 
arm. Using a labeled IV formulation and non-labeled oral tablets 
allowed us to simultaneously administer both formulations and 
characterize TPM PK by each route. This approach also reduces 
interoccasion variability caused by dosing on different days and/
or times (27).
Dose rationale
Based on reports of doses associated with efficacy in human 
SE (2–40 μg/mL), we aimed for a plasma TPM concentration 
on the higher end of the range (20–30  μg/mL) for a higher 
likelihood of efficacy without risking safety (17–23). A previous 
single IV dose study in one dog reported TPM concentrations 
from which we calculated an apparent volume of distribution 
(Vd) of 0.6 L/kg (24). Using this Vd, we estimated that IV doses 
of 10 and 20 mg/kg would produce initial concentrations (C0) 
of ~16 and 32 μg/mL, respectively.
study Design
For low dose IV/oral TPM study, four dogs were used in this study 
(ID 1–4; Table 1). Two of the four dogs were on ASD maintenance 
Table 1 | animal demographics at time of study.
subject age 
(years)
gender Weight 
(kg)
breed seizure type seizure frequency co-medications
1 5 Male,  
intact
33 Coonhound  
mix
Focal, with  
generalized seizures
Generalized cluster seizures once every  
3 weeks
Levetiracetam, 
zonisamide, phenobarbital
2 9 Male,  
neutered
29 Labrador 
retriever mix
Focal, with  
generalized seizures
Focal cluster seizures every 2–4 days. 
With secondarily generalized cluster  
seizures every 1–2 weeks
Levetiracetam, 
zonisamide, 
phenobarbital, potassium 
bromide
3 3 Male,  
intact
15 Beagle N/A Seizure-free and in remission for 2 years  
(had one witnessed generalized seizure)
N/A
4 5 Female,  
spayed
29 Coonhound  
mix
N/A Seizure-free for and in remission 2.5 years  
(had one witnessed generalized seizure)
N/A
5 5 Male,  
intact
35 Coonhound  
mix
Focal, with secondary 
generalized seizures
Single generalized seizures once every  
2–3 months
Phenobarbital
3
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regimen including phenobarbital (PB). Each dog was fasted over-
night prior to receiving a 10 mg/kg dose of stable-labeled IV TPM 
infused over 5 min. One hour following the IV bolus, each dog 
also received a 5 mg/kg dose of unlabeled oral TPM. This delay 
in oral administration was by design to allow evaluation of the IV 
dose on iEEG for 1 h after dosing. Each dog was fed no sooner 
than 2 h after the oral dose. Blood samples (~5 mL) were collected 
from an indwelling catheter prior to dosing and at 0.083, 0.25, 0.5, 
0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 9 h following the IV bolus.
High-Dose IV TPM Study
Three dogs were used in this study (ID 3–5; Table 1). One dog 
was on PB maintenance therapy. Each dog was fasted overnight 
prior to receiving a 20  mg/kg dose of stable-labeled IV TPM 
infused over 5 min. Blood samples (~5 mL) were collected from 
an indwelling catheter prior to dosing and at 0.083, 0.25, 0.5, 0.75, 
1, 1.5, 2, 2.5, 3, 4, 6, 8, and 9 h following the IV bolus.
Diazepam Positive Control
Intravenous diazepam (DZP) (0.5  mg/kg) was administered to 
two dogs that were having uncontrolled seizures (ID 1 and 2) 
during an interictal period as a positive control as it has been 
shown to elicit iEEG change.
TPM Plasma Measurements
Upon sample collection, blood was placed on ice, and plasma 
was separated. All samples were immediately frozen (−20°C) 
until analysis. A high-performance liquid chromatography-mass 
spectrometry (HPLC-MS) method developed and validated at 
the Center for Orphan Drug Research was used to measure TPM 
concentrations in dog plasma. Seven calibration standards (run 
in triplicate) and nine quality control standards (low, medium, 
and high run in triplicates) were prepared in plasma. Study, 
calibration, and quality control samples (250 μL) were extracted 
using methyl tert-butyl ether. TPM and stable-labeled TPM were 
analyzed using the Hewlett Packard Agilent 1100 Model G1946 
liquid chromatography mass spectrometry detection system 
and Agilent ChemStation software. The analytes were separated 
using a Zorbax C18 column (150  mm ×  3.0  mm, 3 μm), and 
the mobile phase consisted of an ammonium acetate buffer and 
methanol. The quantization was performed using the selective 
ion monitoring in the negative mode, with deuterated TPM (d10) 
as the internal standard. The mass-to-charge ratios were 338 and 
244 m/z for TPM and stable-labeled TPM, respectively. The cali-
bration curves were linear (r2 = 0.998) in the concentration range 
of 0.05–50 μg/mL for stable-labeled TPM and 0.05–10 μg/mL 
for TPM in plasma. The limit of detection and quantitation was 
0.05 ng/mL and 0.05 μg/mL, respectively. The precision for both 
TPM and stable-labeled TPM ranged from 3 to 6%, and accuracy 
values were between 95 and 114% and 86 and 105%, respectively.
Pharmacokinetic analysis
Topiramate concentration–time data were analyzed using 
non-compartmental analysis (Phoenix WinNonLin, ver-
sion 6.4, Pharsight Corporation, Mountain View, CA, USA). 
Pharmacokinetic parameter values included maximum concen-
tration (Cmax), time at which maximum concentration is achieved 
(tmax), elimination rate half-life (t1/2), and the area under the 
time–concentration curve (AUCINF) calculated using the equation 
AUC Cp= ×
=
=∞
∫
t
t
dt
0
 (where Cp is the plasma TPM concentration) and 
a linear-log trapezoidal method. Oral bioavailability (F%) was cal-
culated using the equation F %
AUC oral Dose IV
AUC IV Dose oral
( ) = ( )× ( )( )× ( )
×100. 
Clearance (CL) and Vd were calculated using the equations 
CL Dose F
AUC
=
×  and CL =  ke ×  Vd, respectively, where ke is the 
elimination rate constant. Concentration–time profiles were 
created using the GraphPad Prism 7 (Version 7.0a, GraphPad 
Software, Inc., La Jolla, CA, USA).
Pharmacokinetics parameters were also determined using 
population compartmental modeling (Phoenix Non-Linear 
Mixed Effects software, version 1.3, Pharsight Corporation, 
Mountain View, CA, USA). First-order conditional estimation 
extended least squares method was used throughout the model 
building process. One and two compartment models were evalu-
ated. A proportional error model for between subject variability 
was used. Both additive and multiplicative error models for resid-
ual variability were evaluated. The best fit model was determined 
using visual inspection, goodness of fit plots, weighted residual 
FigUre 1 | (a) Plasma TPM concentration time profile following an 
intravenous bolus (low dose: 10 mg/kg) of stable-labeled TPM. (b) Plasma 
TPM concentration time profile following an intravenous bolus (high dose: 
20 mg/kg) of stable-labeled TPM.
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plots, weighted sum of squared residuals, Akaike’s Information 
Criterion, and precision of model parameters.
The presence of a CYP3A4-inducing co-medication (such 
as PB) was evaluated as a covariate for its influence on TPM 
clearance. The relationship of the covariate and TPM clearance 
was modeled by the equation Cl = tvCl × edCl × eηCl, where Cl is 
the clearance from the central compartment, tvCl is the typical 
value of the clearance from the population, dCl is the estimated 
value of the inducer effect, and ηCl is the between-subject vari-
ability (BSV) of clearance. A covariate was considered statistically 
significant if inclusion of the covariate resulted in a decrease in 
the objective function value (OFV) of at least 6.64 (p < 0.01, x2, 
degree of freedom = 1). The final model was used to simulate of 
5-, 10-, and 15-min infusions IV TPM at doses ranging from 10 
to 30 mg/kg.
electroencephalographic analysis
Intracranial electroencephalographic analysis was performed 
in one dog (ID 3) that was not having uncontrolled seizures 
(not on co-medications). Sixteen electrode channels were con-
tinuously sampled at 399.6  Hz. A bandpass filter was applied 
to create six frequency bands: delta (1–4 Hz), theta (4–8 Hz), 
alpha (8–12 Hz), beta (12–25 Hz), low gamma (25–40 Hz), and 
high gamma (40–120  Hz). In order to evaluate differences in 
EEG features, energy of each electrode within each frequency 
band was calculated in 1-s intervals by summing the square of 
the EEG signal amplitude within the 1-s window. The average 
energy level was calculated for three 15-min ranges: starting 
from 15-min pre-dose to dosing, from dosing to 15-min post-
dose, and from 15-min post-dose to 30-min post-dose. The 
difference between averaged energy levels at pre-dose and each 
post-dose interval were calculated. p Values were generated by 
the Kruskal–Wallis test comparing the averaged energy level 
from pre-dose to the two averaged energy levels post-dose. 
While EEG systems were implanted in all dogs, EEG data were 
not attained for all animals due to electrical malfunctioning of 
the electrodes and/or data cards as some of the devices had been 
implanted for up to 5 years.
resUlTs
Demographics and adverse events
Demographics of the dogs are represented in Table 1. No adverse 
events were observed for either dose group throughout the course 
of the study.
non-compartmental PK analysis
The concentration–time profiles of plasma 13C-TPM following 
the low- and high-dose IV infusions are shown in Figure  1. 
Pharmacokinetic parameter estimates using non-compartmental 
analysis are summarized in Table 2. TPM clearance was greater 
and elimination half-life shorter in dogs receiving chronic PB. The 
clearance was 0.5–0.7 versus 0.1 L/h/kg and elimination half-life 
0.5–1 versus 3.7–5 h in dogs with and without PB, respectively, 
suggesting hepatic enzyme induction by PB. Clearance, volume of 
distribution, and elimination half-life were similar for both dose 
groups studied. AUCINF approximately doubled as dose doubled 
suggesting dose-proportional PK.
Plasma TPM concentration–time profiles following oral 
administration are depicted in Figure  2. Cmax following oral 
administration ranged between 1.9 and 2 μg/mL at 1–1.5 h (Tmax), 
with a t1/2 between 1.7 and 2 h in the two dogs on PHB. In the two 
dogs not on PB, a Cmax of 4.7–5.5 μg/mL at 0.5–1 h was observed, 
with a t1/2 of 4 h. Individual oral bioavailability ranged between 
61 and 102%. These results are summarized in Table 3. Similar 
to the IV administration, the two dogs on PHB exhibited higher 
clearance rates, and consequently, shorter half-lives compared to 
the two dogs not on PB.
compartmental PK analysis
A two compartment model with first-order elimination best 
fit the TPM concentration data following IV administration 
(Figure S1 in Supplementary Material). Parameter estimates are 
provided in Table S1 in Supplementary Material. A systematic 
bias in clearance based on dose was observed. The inclusion of 
whether the dog was on an enzyme-inducing co-medication as a 
covariate resulted in a decrease in the OFV from the base model 
Table 2 | Pharmacokinetic parameter values estimated from non-compartmental analysis after an intravenous bolus of stable-labeled TPM.
iD group t1/2 (h) c1 (μg/ml) aUcinF_obs (μg × h/ml) V_obs (l/kg) cl_obs (l/h/kg)
1 LOW 0.47 29.2 13.7 0.50 0.73
2 LOW 0.75 27.1 20.6 0.53 0.49
3 LOW 3.71 30 83.5 0.64 0.12
4 LOW 4.05 28.9 101 0.58 0.1
3 HIGH 4.99 26.1 194 0.74 0.1
4 HIGH 4.52 29.5 176 0.74 0.11
5 HIGH 0.95 25.7 38.4 0.71 0.52
LOW = 10 mg/kg dose; HIGH = 20 mg/kg dose; t1/2, elimination half-life; C1, first measured concentration; AUCINF_obs, observed area under the curve from time 0 to infinity; V_obs, 
observed volume of distribution; Cl_obs, observed clearance.
FigUre 2 | Plasma TPM concentration time profile following an oral 
dose (5 mg/kg) of TPM.
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(difference in OFV = 25) and an improvement in the goodness 
of fit plots and precision of parameter estimates. Therefore, 
the effect of an enzyme inducer on clearance was included in 
the final model. The presence of PB is estimated to affect TPM 
clearance by a factor of 5.64. Except for peripheral compartment 
clearance, all model-fitted parameters were estimated with good 
precision with all coefficients of variation below 25%. A multi-
plicative error model best described the residual error with an 
estimate of 15%, which is consistent with analytical error. Visual 
predictive check plots (Figure S2 in Supplementary Material) 
illustrated the observed data percentiles fall within the 90% 
(5–95%) model-predicted intervals.
simulation analysis
Using the final model above, various infusion rates and doses 
were simulated (Figure 3). For dogs not on enzyme-inducing co-
medications, simulated time-concentration profiles suggest that 
a 5-min infusion of 20 mg/kg would achieve target concentration 
range of 20–30 μg/mL at 30 min post-dose. However, in dogs on 
enzyme-inducing co-medications, a dose between 25 and 30 mg/
kg infused over 5 min would be required to attain the same target 
range.
eeg analysis
In one dog (ID 3), IV TPM produced EEG changes shortly after 
the infusion, which continued in the subsequent 40–60  min 
(Figure S3 in Supplementary Material). Statistically significant 
positive energy differences in all 6 frequency bands across all 16 
channels were seen comparing the pre-dose time (−15–0 min) 
to both post-dose times (0–15  min and 15–30  min) (Table S2 
in Supplementary Material). Detailed energy differences across 
the 6 frequency bands in each of the 16 channels comparing the 
pre-dose time to 0–15 min post-dose are shown in Table S3 in 
Supplementary Material.
DiscUssiOn
This study is unique in that it evaluated the PK of IV and oral 
TPM in dogs with naturally occurring epilepsy. This is also the 
first study that reports the absolute bioavailability of oral TPM 
and the effect of PB on TPM PK in dogs. The oral bioavailability 
was 62–102% that is similar to what has been reported in humans 
(28). Furthermore, enzyme induction increases TPM clearance 
in both humans and dogs. In humans, enzyme-inducing co-
medications such as carbamazepine and phenytoin showed a 1.5-
fold increase in TPM clearance. In our study, PB increased TPM 
clearance by 5.6-fold. To explain this discrepancy, Caldwell et al. 
found that while 82% of TPM is excreted unchanged in the urine 
in humans, only 28% is excreted unchanged in dogs (29). PB is 
a known inducer of CYP 3A4, the major enzyme responsible for 
TPM metabolism. A recent study evaluating the effects of chronic 
administration of PB on the PK of levetiracetam in dogs with 
epilepsy found similar results (30). Potential drug–drug interac-
tions should be taken into consideration when dosing TPM in 
both dogs and humans. Dose adjustments are likely needed when 
TPM is used in conjunction with chronic enzyme-inducing or 
enzyme-inhibiting co-medications in dogs. Although two of the 
dogs on maintenance ASDs were also taking zonisamide and lev-
etiracetam, and these drugs are not known inducers or inhibitors 
of TPM metabolism.
A limitation of this study is the small number of animals as 
is the heterogeneity among the dogs. However, we think our 
animals are more representative of the true population and 
allow us to preliminarily explore the effects of co-administered 
ASDs on TPM PK. Although our population model is based 
on a small number of animals, it provides useful information. 
We based this assertion on prior study, we did with four dogs. 
Using pharmacokinetic data and simulations, we were able to 
predict phenytoin exposure from different fosphenytoin dosing 
strategies and determine the optimal dosing regimen to attain the 
6Vuu et al. IV Topiramate Pharmacokinetics in Dogs
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same phenytoin concentrations that are considered therapeutic 
in human SE in dogs (11). We subsequently used that dosing 
regimen to attain the targeted phenytoin concentration in a 
randomized safety and efficacy clinical trial (31). Based on case 
reports of TPM oral suspensions used to treat refractory SE, our 
goal target concentration range was 20–30 μg/mL. Our simula-
tions suggest that these doses should be used in designing future 
a clinical trial in canine SE. Further evidence of the appropriate-
ness of the population model is that the precision of the model 
parameters, and other goodness of fit criteria did not show any 
major model misspecifications.
Although we were only able to assess iEEG in one dog, the 
significant changes between pre-dose EEG energy levels and 
those up to 30  min after IV TPM administration suggest suf-
ficient diffusion into the brain. This observation warrants further 
study in additional animals. Benzodiazepines in both rodent and 
dog model show significant increases in energy in frequencies 
greater than 4 Hz and decreases in delta frequency energy, as we 
saw in this one dog. These observations suggest IV TPM may be 
beneficial for the treatment of SE.
In conclusion, IV TPM doses of 10 and 20 mg/kg infused over 
5 min were shown to be safe and tolerable in dogs. Concurrent 
administration of PB increased the clearance of TPM ~5.6-fold. 
Simulations suggest that doses of 20 and 25 mg/kg of IV TPM 
are necessary to achieve a target concentration between 20 and 
30 μg/mL in dogs not on PB and dogs on PB, respectively. A key 
strength of this study is the use of animals with naturally occur-
ring epilepsy. The results of this study provide information on 
optimizing TPM therapy for future studies of canine SE, which 
will subsequently guide the design of IV TPM clinical trials of 
human SE. Future work includes conducting a phase II/III effi-
cacy study in canine SE using the dose strategy determined from 
the PK modeling results of this study.
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Table 3 | Pharmacokinetic parameter values estimated from non-compartmental analysis after an oral dose (5 mg/kg) of unlabeled TPM.
iD t1/2 (h) Tmax (min) Cmax (μg/ml) aUcinF_obs (μg × h/ml) V_obs (l/kg) cl_obs (l/h/kg) F (%)
1 2.02 90 1.92 4.73 2.13 0.73 69.2
2 1.66 60 2.08 10.5 1.16 0.49 102
3 3.98 30 4.73 25.7 0.69 0.12 61.7
4 4.08 60 5.53 36.9 0.58 0.1 73.0
Volume and clearance were adjusted for bioavailability.
t1/2, elimination half-life; Tmax, time at peak concentration; Cmax, peak concentration, AUCINF_obs, observed area under the curve from time 0 to infinity; V_obs, observed volume of 
distribution; Cl_obs, observed clearance; F, bioavailability.
FigUre 3 | Population pharmacokinetic parameters used for the 
simulations: volume of distribution (Vd) of central compartment =  
376 ml/kg, Vd of peripheral compartment = 298 ml/kg, clearance 
(cl) from central compartment = 1.84 mg/(kg × min), cl from 
peripheral compartment = 21 ml/(kg × min), and effect of Pb 
presence on cl = 1.73. (a) Simulations of plasma concentration–time 
profiles following 5-min infusions of different doses in a dog not on 
enzyme-inducing co-medications. Here, the desired range is represented by 
the black dashed lines, and the black vertical line denotes 30 min post-dose. 
(b) Simulations of plasma concentration–time profiles following 5-min 
infusions of different doses in a dog on enzyme-inducing co-medications. 
Here, the desired range is represented by the black dashed lines, and the 
black vertical line denotes 30 min post-dose.
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FigUre s1 | (a) Observed versus individual predicted concentrations derived 
from the two compartment model using a population approach. (b) Observed 
versus population predicted concentrations derived from the two compartment 
model using a population approach.
FigUre s2 | (a) Visual predictive check of the population two 
compartment model following an intravenous bolus of TPM for a dog not 
on inducing co-medications. Here, the observed quantiles (red lines) are 
superimposed with the predictive check quantiles (black lines) over the 
observed data (blue circles). (b) Visual predictive check of the population 
two compartment model following an intravenous bolus of TPM for a dog 
on inducing co-medications. Here, the observed quantiles (red lines) are 
superimposed with the predictive check quantiles (black lines) over the 
observed data (blue circles).
FigUre s3 | electroencephalograph normalized signals from beta and 
low gamma frequency bands averaged over 1-min intervals in one dog.
Table s1 | Pharmacokinetic parameter estimates estimated from a 
population two compartment analysis following an intravenous bolus of 
TPM, pooling together low- and high-dose data. tvV, typical value of volume 
of distribution from central compartment; tvCl, typical value of clearance from 
central compartment; dCl, effect of PB presence on Cl; BSV, between-subject 
variability; CV%, coefficient of variation; RSE%, relative standard error.
Table s2 | Difference between energy levels averaged across each 
frequency band. An asterisk (*) denotes the differences were statistically 
significant across all channels.
Table s3 | Differences between the averaged energy levels at 15 min 
pre-dose (−15 to 0 min) and 15 min post-dose (0 to +15 min) and their 
p-value (probability of having a difference that large or more extreme).
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